
Pharmacally
MSA
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in MSA
Clinical TrialsFDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSAThe FDA has endorsed Alterity Therapeutics’ Phase 3 strategy for ATH434 in Multiple System Atrophy (MSA), agreeing on study population, dosing, endpoints, and safety database requirements.Fact-Checked
Clinical TrialsOno Reports Encouraging Phase 2 Results for ONO-2808 in MSAOno Pharmaceutical Co., Ltd. presented new Phase 2 results for ONO-2808, a selective S1P5 agonist, in patients with multiple system atrophy (MSA) at the 7th World Parkinson Congress.…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.